TH126338A - - Google Patents
Info
- Publication number
- TH126338A TH126338A TH901003267A TH0901003267A TH126338A TH 126338 A TH126338 A TH 126338A TH 901003267 A TH901003267 A TH 901003267A TH 0901003267 A TH0901003267 A TH 0901003267A TH 126338 A TH126338 A TH 126338A
- Authority
- TH
- Thailand
- Prior art keywords
- substances
- signal transduction
- spirocyclic
- salts
- formula
- Prior art date
Links
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 2
- 229960000367 inositol Drugs 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 150000007522 mineralic acids Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000001173 tumoral effect Effects 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
Abstract
DC60 (27/07/54) การประดิษฐ์นี้เกี่ยวข้องกับสไปโรไซคลิก เฮเทอโรไซเคิล (spirocyclic heterocycles) ที่มีสูตร ทั่วไป(I) (สูตรเคมี) (I), ทอโทเมอร์, สเตริโอไอโซเมอร์, ของผสมของสารเหล่านี้และเกลือของสารเหล่านี้, โดยเฉพาะ เกลือ ที่ยอมรับได้ทางสรีรวิทยาของสารเหล่านี้ด้วยกรดอินทรีย์หรืออนินทรีย์, ซึ่งมีสมบัติทางเภสัชวิทยา ที่มีคุณค่า, โดยเฉพาะ ผลในการยับยั้งการส่งทอดสัญญาณ (signal transduction) ที่สื่อให้เกิดขึ้นโดย ไทโรซีนไคเนส, การใช้สารเหล่านี้เพื่อการบำบัดโรค, โดยเฉพาะ โรคเนื้องอก (tumoral diseases) รวมทั้งภาวะต่อมลูกหมากโตชนิดไม่ร้าย (BPH), โรคปอดและทางเดินหายใจ, และการเตรียมสาร เหล่านี้ การประดิษฐ์นี้เกี่ยวข้องกับสไปโรไซคลิก เฮเทอโรไซเคิลที่มีสูตรทั่วไป(I) (สูตร) (I), ทอโทเมอร์, สเตริโอไอไซเมอร์, ของผสมของสารเหล่านี้และเกลือของสารเหล่านี้, โดยเฉพาะ เกลือที่ยอมรับได้ทางสรีรวิทยาของสารเหล่านี้ด้วยกรดอินทรีย์หรืออนินทรีย์, ซึ่งมีสมบัติ ทางเภสัชวิทยาที่มีคุฯค่า, โดยเฉพาะ ผลในการยับยั้งการส่งทอดสัญญาณ (signal transduction) ที่สื่อ ให้เกิดขึ้นโดยไทโรซีนไคเนส, การใช้สารเหล่านี้เพื่อการบำบัดโรค, โดยเฉพาะ โรคเนื้องอก (tumoral diseases) รวมทั้งภาวะต่อลุกหมากโตชนิดไม่ร้าย (BPH), โรคปอดและทางเดินหายใจ, และ การเตรียมสารเหล่านี้ สิทธิบัตรยา DC60 (27/07/54) This invention relates to spirocyclic. Heterocyclic (spirocyclic heterocycles) with the general formula (I) (chemical formula) (I), inositol, sterioisomer, mixtures of these substances and salts of These substances, in particular the physiologically acceptable salts of them with organic or inorganic acids, have valuable pharmacological properties, in particular their effect on signal transduction (signal transduction) that Make it happen by Tyrosine kinases, their therapeutic use, especially tumoral diseases including benign prostatic hyperplasia (BPH), lung and respiratory diseases, and their preparations. These invention relate to spirocyclic. Generalized heterocycles (I) (formula) (I), inositol, sterioisomer, mixtures of these substances and salts of them, In particular, the physiologically acceptable salts of these substances with organic or inorganic acids, which have qualitative pharmacological properties, in particular their effect on signal transduction (signal transduction) conveyed. It is formed by tyrosine kinase, the therapeutic use of these substances, especially tumoral diseases including non-malignant hyperlipidemia (BPH), lung and respiratory diseases, and Preparation of these substances, drug patents
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH126338A true TH126338A (en) | 2013-08-19 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aronov et al. | Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors | |
| Kraege et al. | The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2) | |
| EA201001241A1 (en) | SPIROHETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION | |
| EA200901608A1 (en) | DERIVATIVES OF CHINAXOLINE AS AN INHIBITORS THYROZINKINASE ACTIVITY OF JANUS KINASE | |
| WO2008078100A3 (en) | Tricyclic amine derivatives as protein tyrosine kinase inhibitors | |
| CL2008001230A1 (en) | Compounds derived from pyrrole (2.3-d) pyrimidine. purin-6-yl or pyrazol (3,4-d) pyrimldine, p70 s6 kinase inhibitors; pharmaceutical composition; and use for the preparation of drugs useful in the treatment of colon adenocarcinomas and inhibition of angiogenesis. | |
| YU49603A (en) | HINAZOLINE DERIVATIVES, THE MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PREPARATION | |
| EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
| EA201391470A1 (en) | SUBSTITUTED SALTS 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE | |
| EA201300872A1 (en) | DIMALEAT 9- [4- (3-Chlor-2-Fluoro-phenylamino) -7-METHOXYHINAZOLIN-6-ILOXI] -1,4-Diazaspiro [5.5] UNDECAN-5-SHE, ITS USE AS A MEDICINE MEDICINE HEAT | |
| Osman et al. | Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone‐based derivatives as DHFR inhibitors | |
| UY26902A1 (en) | BICYCLIC HETEROCYCLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURES FOR THEIR PREPARATION | |
| UY28191A1 (en) | BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION. | |
| TW200730508A (en) | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | |
| Marques et al. | Targeting vascular endothelial growth factor receptor 2 (VEGFR-2): Latest insights on synthetic strategies | |
| ECSP099562A (en) | BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, ITS USE AND PROCEDURES FOR THEIR PREPARATION | |
| El-Damasy et al. | ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles | |
| Gryshchenko et al. | Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1, 2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1 | |
| Modh et al. | Synthesis and Evaluation of Novel 4‐Substituted Styryl Quinazolines as Potential Antimicrobial Agents | |
| Giordanetto et al. | Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation | |
| DE602007001952D1 (en) | 7H-PYRIDOÄ3,4-DÜPYRIMIDIN-8-ONE, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE INHIBITORS | |
| ECSP045330A (en) | BICYCLIC HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR THEIR PREPARATION | |
| Houghton et al. | Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program | |
| TH126338A (en) | ||
| WO2007023073A3 (en) | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |